Wednesday, May 15, 2013

• Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood CancerBusiness Wire( (Wed, May 15)
• Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCOBusiness Wire( (Wed, May 15)

Tuesday, May 14, 2013

• FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung CancerBusiness Wire( (Tue, May 14)

Tuesday, April 30, 2013

• FDA Approves ACTEMRA® for Children Living with a Rare Form of ArthritisBusiness Wire( (Tue, Apr 30)

Monday, April 8, 2013

• Roche and Isis Pharmaceuticals form alliance for Huntington's diseasePR Newswire( (Mon, Apr 8)

Friday, March 8, 2013

• Tucson Symposium attracts over 450 global scientists focused on personalized healthcarePR Newswire( (Fri, Mar 8)

Tuesday, February 26, 2013

• Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesionsPR Newswire( (Tue, Feb 26)

Sunday, February 24, 2013

• Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic Form of Hives who Failed Standard TherapyBusiness Wire( (Sun, Feb 24)

Friday, February 22, 2013

• FDA Approves Genentech’s Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast CancerBusiness Wire( (Fri, Feb 22)

Monday, February 18, 2013

• Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin® for acromegaly and neuroendocrine tumorsPR Newswire( (Mon, Feb 18)

Tuesday, February 12, 2013

• RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug CompoundsPR Newswire( (Tue, Feb 12)

Thursday, January 31, 2013

• Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People With Chronic Lymphocytic Leukemia (CLL)Business Wire( (Thu, Jan 31)